Actively Recruiting
Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI
Led by Tata Memorial Centre · Updated on 2025-04-09
101
Participants Needed
1
Research Sites
357 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to evaluate the role of memantine in preservation of memory and neurocognition in patients undergoing craniospinal irradiation. Participants will be randomised into two arms and the interventional arm will receive memantine along with the standard treatment. Researchers will compare the neurocognitive tests of participants in both the arms to see if memantine leads to significant preservation of memory and cognition post radiation therapy.
CONDITIONS
Official Title
Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age at irradiation between 5 and 39 years
- Planned for craniospinal irradiation (CSI) with or without boost dose and with or without systemic chemotherapy
- Informed consent or assent obtained
- Karnofsky Performance Status or Lansky Performance Status score of 60 or higher
You will not qualify if you...
- Prior craniospinal re-irradiation
- Previous exposure to memantine
- Unable to undergo Wechsler neurocognitive test
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tata Memorial Hospital
Mumbai, Maharashtra, India, 400012
Actively Recruiting
Research Team
T
Tejpal Gupta, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here